Atara Biotherapeutics, Inc. (0HIY.L)
USD 10.43
(-0.02%)
USD 10.43
(-0.02%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 57.87 Million USD | -19.29% |
| 2022 | 71.7 Million USD | 180.99% |
| 2021 | 25.51 Million USD | 95.68% |
| 2020 | 13.04 Million USD | -7.75% |
| 2019 | 14.13 Million USD | 1815.45% |
| 2018 | 738 Thousand USD | 47.6% |
| 2017 | 500 Thousand USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 89.83 Million USD | -42.93% |
| 2024 Q1 | 92.34 Million USD | 59.56% |
| 2023 Q1 | 54.91 Million USD | -23.41% |
| 2023 Q3 | 61.8 Million USD | -4.49% |
| 2023 FY | 57.87 Million USD | -19.29% |
| 2023 Q4 | 57.87 Million USD | -6.36% |
| 2023 Q2 | 64.7 Million USD | 17.83% |
| 2022 Q1 | 17.45 Million USD | -31.61% |
| 2022 Q3 | 61.07 Million USD | -4.57% |
| 2022 Q2 | 63.99 Million USD | 266.69% |
| 2022 FY | 71.7 Million USD | 180.99% |
| 2022 Q4 | 71.7 Million USD | 17.41% |
| 2021 Q2 | 12.18 Million USD | -3.08% |
| 2021 FY | 25.51 Million USD | 95.68% |
| 2021 Q1 | 12.56 Million USD | -3.62% |
| 2021 Q4 | 25.51 Million USD | 3.84% |
| 2021 Q3 | 24.57 Million USD | 101.72% |
| 2020 Q2 | 13.42 Million USD | -2.82% |
| 2020 Q4 | 13.04 Million USD | -0.67% |
| 2020 FY | 13.04 Million USD | -7.75% |
| 2020 Q3 | 13.12 Million USD | -2.17% |
| 2020 Q1 | 13.8 Million USD | -2.31% |
| 2019 Q4 | 14.13 Million USD | -2.73% |
| 2019 Q3 | 14.53 Million USD | -2.59% |
| 2019 Q2 | 14.91 Million USD | 3.34% |
| 2019 Q1 | 14.43 Million USD | 0.0% |
| 2019 FY | 14.13 Million USD | 1815.45% |
| 2018 FY | 738 Thousand USD | 47.6% |
| 2018 Q4 | - USD | -100.0% |
| 2018 Q3 | 10.3 Million USD | 0.0% |
| 2018 Q2 | 10.3 Million USD | 0.0% |
| 2018 Q1 | 10.3 Million USD | 0.0% |
| 2017 FY | 500 Thousand USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -58.397% |
| Dynavax Technologies Corporation | 256.91 Million USD | 77.474% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -39.36% |
| Perrigo Company plc | 4.07 Billion USD | 98.579% |
| Illumina, Inc. | 2.26 Billion USD | 97.442% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.834% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -5687.2% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.394% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.593% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 66.693% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 97.859% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -114.42% |
| Waters Corporation | 2.35 Billion USD | 97.543% |
| Biogen Inc. | 7.33 Billion USD | 99.211% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -51.879% |
| Evolus, Inc. | 126.54 Million USD | 54.268% |
| Adicet Bio, Inc. | 17.7 Million USD | -226.905% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -34.065% |
| bluebird bio, Inc. | 330.32 Million USD | 82.48% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 89.302% |
| FibroGen, Inc. | 170.45 Million USD | 66.049% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 97.884% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -177.109% |
| Homology Medicines, Inc. | 44.05 Million USD | -31.366% |
| Geron Corporation | 85.89 Million USD | 32.628% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 97.587% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 86.997% |
| Myriad Genetics, Inc. | 145 Million USD | 60.088% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -4493.016% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 49.827% |
| Zoetis Inc. | 6.8 Billion USD | 99.149% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -1214.675% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 97.33% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 94.896% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 92.841% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -59.326% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 96.019% |
| Verastem, Inc. | 41.55 Million USD | -39.259% |
| Nektar Therapeutics | 230.4 Million USD | 74.882% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 68.948% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -1782.628% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 95.857% |
| OPKO Health, Inc. | 326.56 Million USD | 82.279% |
| Exelixis, Inc. | 189.94 Million USD | 69.532% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 86.491% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -38225.828% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | 58.188% |
| Imunon, Inc. | 1.13 Million USD | -4979.641% |
| Blueprint Medicines Corporation | 774.12 Million USD | 92.524% |
| Insmed Incorporated | 1.2 Billion USD | 95.193% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 96.14% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -1.551% |
| TG Therapeutics, Inc. | 110.79 Million USD | 47.767% |
| Incyte Corporation | 38.28 Million USD | -51.153% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 93.405% |